Clinical Report: Impact of MEK-inhibitor Therapy on Lymphatic Abnormalities in Infants Diagnosed with Noonan Syndrome
Overview
This study evaluates the effects of MEK inhibitor Trametinib on lymphatic abnormalities in infants with Noonan syndrome. After one year of treatment, clinical improvements were observed, although imaging showed limited anatomical changes.
Background
Noonan syndrome (NS) is a genetic disorder that often presents with lymphatic complications, leading to clinical issues such as chylous effusions. Current treatment options for these lymphatic manifestations are limited, making the exploration of targeted therapies like MEK inhibitors important. This study aims to assess the efficacy of Trametinib in managing lymphatic disease in infants with NS.
Data Highlights
Parameter
Baseline
1-Year Follow-Up
Clinical Improvement
All patients
All patients
Chest Drainage Required
All patients
None
Residual Fluid
All patients
3 with none, 3 with minimal
Lymphatic Perfusion Rating (Median)
3
1
Key Findings
Six infants with genetically confirmed Noonan syndrome were treated with Trametinib.
All patients showed clinical improvement after one year of therapy.
No patients required chest drainage during the follow-up period.
MR lymphangiography indicated a decrease in pleural effusions in all cases.
Lymphatic imaging did not show normalization of lymphatic anatomy or flow.
Clinical Implications
The findings indicate that Trametinib may be a treatment option for infants with Noonan syndrome experiencing lymphatic abnormalities. However, the lack of normalization in lymphatic anatomy highlights the need for further evaluation.
Conclusion
Trametinib therapy resulted in clinical improvements in infants with lymphatic abnormalities associated with Noonan syndrome, although imaging showed limited anatomical changes over one year.
